Vaccinating Children Against Ebola: Is Protection Both Effective and Safe?

By Ana Espino | Published on June 16, 2026 | 4 min read

Ebola virus disease remains one of the deadliest infectious diseases known, with mortality rates reaching up to 90% during certain outbreaks. Children are among the most vulnerable populations: mortality can exceed 80% in children under five years of age, while their management remains particularly challenging in emergency settings.

Since the major West African Ebola outbreak of 2013–2016, the development of Ebola vaccines has accelerated considerably. Several vaccines are now available or in use, but data regarding their effectiveness and safety in children have remained fragmented. To better inform vaccination strategies, Italian researchers conducted the first meta-analysis specifically focused on the immunogenicity and safety of Ebola vaccines in pediatric populations.


Also read: Ebola: Why Do Some Patients Survive While Others Succumb to the Disease?

Robust Immune Responses in More Than 110,000 Children

The researchers analyzed seven datasets derived from clinical trials and follow-up studies involving more than 110,000 children and adolescents vaccinated against Ebola. The vaccines evaluated included the rVSVΔG-ZEBOV vaccine (Ervebo) and the two-dose Ad26.ZEBOV/MVA-BN-Filo vaccination regimen.

The results showed that after a single dose, nearly 89% of children developed a detectable immune response against the virus. Following completion of the vaccination schedule, this proportion increased to 96%, confirming the strong ability of these vaccines to stimulate the production of protective antibodies.

One year after vaccination, immune protection remained high, with seroconversion rates still exceeding 90%, despite a slight decline over time.

Comparative analyses also suggested that rVSVΔG-ZEBOV induces a more rapid immune response after the first injection, which may be particularly advantageous during outbreaks where rapid protection of exposed populations is essential. The Ad26.ZEBOV/MVA-BN-Filo regimen, meanwhile, achieves very high levels of protection once the full vaccination course has been completed.

Regarding safety, the findings are particularly reassuring. Serious adverse events were rare, occurring in approximately 1% of participants. Moreover, most reported serious events were not directly related to vaccination but rather to other common infections prevalent in the study regions, such as malaria.


   Also read: Ebola: Does the Route of Infection Influence Disease Severity?

Toward the Integration of Children into Ebola Vaccination Strategies?

This meta-analysis confirms that currently available Ebola vaccines are both highly immunogenic and well tolerated in children. The findings support their use not only during outbreak-response vaccination campaigns but also as part of preparedness strategies in countries at risk of future Ebola outbreaks. However, the authors highlight several limitations. The available studies used different immunological assessment methods, making certain comparisons difficult. Data concerning infants under one year of age remain very limited, as does information regarding the actual duration of protection beyond one year.

Despite these uncertainties, the results reinforce the idea that children should no longer be considered a secondary population in Ebola epidemic prevention efforts. Future research will need to clarify the duration of vaccine-induced protection, the potential value of booster doses, and the best approaches for integrating Ebola vaccines into pediatric immunization programs in at-risk regions.


About the author – Ana Espino
PhD in Immunology, specialized in Virology  
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions.